Pelareorep + Gemcitabine/Nab-Paclitaxel + Atezolizumab

About Oncolytics Biotech

Oncolytics Biotech is singularly focused on developing its first-in-class, intravenously delivered oncolytic reovirus, pelareorep, as a platform immunotherapy for gastrointestinal (GI) tumors. The company has generated compelling clinical data across multiple GI cancers, including metastatic pancreatic ductal adenocarcinoma (mPDAC), KRAS-mutant metastatic colorectal cancer (mCRC), and squamous cell carcinoma of the anus (SCAC), demonstrating survival benefits that significantly exceed historical benchmarks. Its strategy is to advance these programs into registration-focused studies, leveraging Fast Track Designation in pancreatic and colorectal cancer to potentially accelerate the path to market.

Therapeutic Areas

Other First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Drugs